Login to Your Account

Shield Raises $13.9M, Gains Phase II Candidate from MRC

By Nuala Moran
Staff Writer

Tuesday, March 6, 2012
LONDON – Shield Therapeutics Ltd. signed an exclusive agreement with the UK Medical Research Council (MRC) for PT20, a treatment for hyperphosphatemia caused by kidney disease, and raised €10.5 million (US$13.9 million) for the onward development of the compound, which is ready for Phase II.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription